Fobrepodacin

N/A

Report date: 2026/01/07 17:54:46
NMEQIDP

Base Information

Drug NameFobrepodacin
Drug Alias NamepVXc-486SPR-720VXc-100VXc-486SPR-719
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionBacterial DNA gyrase inhibitors
TargetsBacterial DNA gyrase
Therapy Area/IndicationsLung DiseasesMycobacterium avium-intracellulare InfectionMycobacterium Infections, Nontuberculous
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesHealthCare Royalty Management LLCSpero Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsLung DiseasesMycobacterium avium-intracellulare InfectionMycobacterium Infections, Nontuberculous

Other Information

ATC CodeN/A
Related LinksN/A